

S&P Dow Jones Indices

A Division of **S&P Global**

S&P Biotechnology Select Industry Index

- i. **Does the S&P Biotechnology Select Industry reference 25 or more component securities (whether or not the security is an underlying security)?**

As of Jan. 3, 2022, the S&P Biotechnology Select Industry consisted of 188 securities from 188 companies.

- ii. **Does the S&P Biotechnology Select Industry reference long positions only?**

The S&P Biotechnology Select Industry references long positions only.

- iii. **Does the S&P Biotechnology Select Industry include any component underlying securities that represent more than 15% of the weight of the component securities in the index?**

As of Jan. 3, 2022, the largest weight of any individual component security of the S&P Biotechnology Select Industry represented 1.4% of the weight of the overall index.

- iv. **Does the S&P Biotechnology Select Industry include five or fewer component underlying securities that together represent more than 40% of the weight of the component securities in the index?**

As of Jan. 3, 2022, the cumulative weight of the five largest securities in the S&P Biotechnology Select Industry represented 5.3% of the overall index weight.

- v. **Is the S&P Biotechnology Select Industry modified or rebalanced only according to publicly stated, predefined criteria, which may require interpretation by the index provider or a board or committee responsible for maintaining the index?**

The S&P Biotechnology Select Industry methodology document describes the criteria for managing the index and includes rebalancing rules and the rules for adding or dropping securities, as well as the manner in which corporate actions on such securities are handled.

- vi. **Is the S&P Biotechnology Select Industry referenced by futures contracts or options contracts that trade on a national securities exchange that is registered with the Securities and Exchange Commission or a domestic board of trade that is designed as a contract market by the Commodity Futures Trading Commission (regardless of whether the contracts provide price only or total return exposure to the index or provide for dividend reinvestment in the index)?**

As of July 5, 2022, the S&P Biotechnology Select Industry was not referenced in any futures contract traded on the Chicago Mercantile Exchange.

- vii. **Did the S&P Biotechnology Select Industry provide an annual dividend yield in the immediately preceding calendar year from component underlying securities that is greater than 1.5 times the annual dividend yield of the S&P 500® as reported for the immediately preceding calendar year?**

The S&P 500 annual dividend yield (which was computed for trailing 2021) was 1.27% and the S&P Biotechnology Select Industry annual dividend yield (which was computed for trailing 2021) was 0.11%. Therefore, the S&P Biotechnology Select Industry did not provide an annual dividend yield in the immediately preceding calendar year from component underlying securities that is greater than 1.5 times the annual dividend yield of the S&P 500.

S&P Dow Jones Indices does not provide tax, legal, or accounting advice. This content is provided as of July 5, 2022, and has been prepared for informational purposes only. An appropriate advisor should be consulted to evaluate the impact of any tax consequences of making any particular investment decision. All information provided by S&P Dow Jones Indices is impersonal and not tailored to the needs of any person, entity, or group of persons. It is not intended to be, and should not be relied upon as, tax, legal, or accounting advice and you should consult your own advisors before engaging in any transaction. Neither S&P Dow Jones Indices LLC nor any of its affiliates shall have any liability for any errors or omissions in the data included therein.